Peripheral Arterial Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 22 years of age or older.
- People who have active bleeding in blood vessels outside the brain and heart, confirmed by imaging (such as a scan or camera procedure), and where a procedure to block the bleeding vessel is considered appropriate by the treating doctor.
- People who are able to provide written consent to take part, either personally or through a legally authorised representative.
- People whose life expectancy is considered to be more than 30 days at the time of enrolling, in the opinion of the treating doctor.
- People whose target treatment area has not previously been treated with an embolization procedure.
Who may not be able to join:
- People who are pregnant or breastfeeding.
- People who currently have signs or symptoms of an active infection.
- People who are already taking part in another clinical trial involving an investigational drug, biological treatment, or medical device.
- People who have an allergy to contrast dye, or another reason they cannot safely undergo angiography, CT scanning, or catheterisation, including contrast sensitivity that cannot be adequately managed before the procedure.
- People who have a known allergy to the components of Onyx™ (the medical device used in this trial).
- People whose blood vessels in the target treatment area are not considered suitable for delivery of Onyx™, based on the treating doctor's assessment.
- People who, in the treating doctor's opinion after reviewing imaging, have more than four target areas that would require treatment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Osman Ahmed, MD, University of Chicago
Phone: 7322662503
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Freedom from Arterial Hemorrhage; Freedom from System-related Major Adverse Events (MAE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.